Clinical Network Services launches new office near London

CNS welcome Paul Cronin who, having worked for highly regarded European regulatory consultancy companies, is very experienced in regulatory affairs and product development, in particular with complex biologics. As well as driving global Business Development for CNS, Paul will lead the European BioDesk team in support of CNS clients requiring access to the European regulatory agencies as well as European clients seeking entry to Australia and New Zealand. The location of the European office is of key importance with regards to European regulatory activities as it allows for easy access to the European Medicines Agency (EMA) and the UK MHRA both of which are based in London.

Otto Damsma led Biometrics and IT at Yamanouchi/Astellas in Europe for more than a decade while Glynn Morrish is a leading Australian Pharmacometrician and Biostatistician. Together they form a strong Biometrics team providing an optimised customer centric service making use of a globally recognised suite of electronic data capture solutions and data analysis tools.

Mark Reid, Director, BioDesk and Regulatory Affairs, commented:

"It really is superb having Paul, Otto and Glynn join CNS. These appointments have further expanded BioDesk's ability to engage European regulators and to bring expert statistical and PK/PD modelling capabilities to early stage product development. I'm very pleased with the early impact these appointments have had as BioDesk continues to solve complex product development problems for our clients."

Paul Cronin, new UK Director and Director, Business Development added:

"I'm really pleased to be joining such a dynamic team and look forward to working closely with Mark and the Australian and UK operational teams to develop the CNS business across Europe and more generally the northern hemisphere."

Russell Neal, Managing Director of CNS concluded:

"By opening the UK office and making these three strategic hires; CNS is fast becoming the leading Australian supplier of strategic product development advice and early stage clinical development support to small to medium sized biotechnology companies. Paul is widely regarded in international and local industry circles and Otto and Glynn are both considered experts in their fields, bringing a wealth of knowledge to our team that will deliver an ongoing advantage of our clients at home and abroad."

Source: Clinical Network Services